News

SA hospital system’s nonprofit owner taps new CEO with close ties

Jaime Wesolowski is putting off retirement to become the new CEO of Methodist Healthcare Ministries of ...

StemBioSys CEO: Company has room to grow in San Antonio

Bob Hutchens is CEO of StemBioSys Inc. CARLOS JAVIER SANCHEZ | SABJ By W. Scott Bailey – Senior ...

Events

Medical Devices 101: An Educational Forum

When:  8:00 – 5:00 pm Monday, August 13 Where:  Norris Conference Center, ...
News
BME Announces Issuance Of Patent For The Speed™ Continuous Active Compression System
November 22, 2013

SAN ANTONIO, Texas, Nov. 22, 2013 /PRNewswire/ -- BME, Inc. (BioMedical Enterprises, Inc., www.bme-tx.com) is the privately held U.S. leader in shape memory technology for small bone fixation, and the first and only U.S.-based manufacturer of Nitinol implants for use in the foot, hand and wrist. As part of its SpeedTM and SpeedTM ShiftTM (fully-disposable continuous active compression system) brands, BME today announces the issuance of U.S. patent #8,584,853, "Method and apparatus for an orthopedic fixation system." This patent relates to the combination of a compressive implant pre-loaded on an insertion device and packaged sterile, promoting efficiencies within the hospital surgical suite.

"This patent acknowledges and rewards the ingenuity fostered within a small company environment," said Keith M. Peeples, President and CEO of BME. The patent helps establish the foundation needed to build the most comprehensive Continuous Active Compression System, which will meet the expanding needs of surgeons and their patients. Mr. Peeples continued, "Innovation is the driving force required to deliver clinically relevant surgical solutions."

BME will continue to aggressively focus on developing a product pipeline which defines our commitment to bringing innovative technology to the extremity market not only in implant design, but in application and delivery.

About BME, Inc.
BME, Inc. is the only U.S. manufacturer of Nitinol metal implants for musculoskeletal fixation. For over a decade, BME has spearheaded the innovation of Nitinol technologies in the U.S. market, and continues the advancement of Nitinol implants and related instruments.

For more information about this announcement and/or BME, Inc., please contact Lisa C. Thompson, Vice President of Marketing, at: lthompson@bme-tx.com or call 484-241-1411.
SOURCE BME, Inc.

 

Stay informed. Subscribe to BioMed SA news alerts.